मूलभूत आँकड़े
| LEI | 5493005LRKM6BCABC605 |
| CIK | 728387 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Perspective Therapeutics, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C |
|
| September 4, 2025 |
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer Distinguished career as a Wall Street analyst and significant CFO experience, bringing keen insights and understanding of finance and the life sciences investment landscape SEATTLE, September 04, 2025 - Perspective Therapeutics, Inc. |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C |
|
| September 3, 2025 |
Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors SEATTLE – September 03, 2025 – Perspective Therapeutics, Inc. |
|
| September 2, 2025 |
Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti |
|
| September 2, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 13, 2025 |
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results • [212Pb]VMT-α-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33407 PER |
|
| August 13, 2025 |
Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti |
|
| August 1, 2025 |
Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti |
|
| August 1, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 3, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 03, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 3, 2025 |
Corporate Presentation July 2025 NYSE AMERICAN: CATX Corporate Presentation July 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. |
|
| June 23, 2025 |
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting SEATTLE – June 21, 2025 – Perspective Therapeutics, Inc. |
|
| June 23, 2025 |
Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti |
|
| June 23, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 23, 2025 |
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial • [212Pb]VMT‑α‑NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 • Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & |
|
| June 23, 2025 |
[212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2 positive tumors in the VMT-α-NET-T101 trial Stephen A. |
|
| June 3, 2025 |
Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti |
|
| June 3, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 30, 2025 |
Investor Call ASCO 2025 Presentation Investor Call ASCO 2025 Presentation Developing the Next Generation of Targeted Therapies Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Neuroendocrine Tumors: VMT-⍺-NET NETs Trials Interim safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor |
|
| May 30, 2025 |
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting • Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2. |
|
| May 30, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Perspective Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33407 (Commission File Number) 41-1458152 (I.R.S. Employer Identification No.) 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 (Address |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33407 PE |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 12, 2025 |
Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti |
|
| May 12, 2025 |
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results • First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platform |
|
| May 1, 2025 |
Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti |
|
| May 1, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 29, 2025 |
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors SEATTLE – April 29, 2025 – Perspective Therapeutics, Inc. |
|
| April 29, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 11, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 11, 2025 |
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1. |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No. |
|
| March 28, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K/A Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001 |
|
| March 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 26, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Perspective Therapeutics, Inc. |
|
| March 26, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-33407 Perspective |
|
| March 26, 2025 |
Exhibit 10.29 2401 Elliott Ave. - Suite 320 Seattle, WA 98121 Phone: (206) 676 - 0900 Toll Free: (877) 447 - 6729 https://perspectivetherapeutics.com EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made by and between Juan Graham (“Executive”) and Perspective Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is effective as of January 6, 2025 (the “Effectiv |
|
| March 26, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Perspective Therapeutics, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), |
|
| March 26, 2025 |
Exhibit 21.1 Subsidiaries of the Company California Alpha Targeted Therapies, LLC, a Delaware limited liability company Illinois Alpha Targeted Therapies, LLC, a Delaware limited liability company Isoray Medical, Inc., a Delaware corporation Isoray International, LLC, a Washington limited liability company Perspective Therapeutics Pty Ltd, an Australian Company Texas Alpha Targeted Therapies, LLC, |
|
| March 26, 2025 |
Exhibit 19.1 PERSPECTIVE THERAPEUTICS, INC. INSIDER TRADING POLICY Amended & Restated as of March 24, 2025 Purpose This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of Perspective Therapeutics, Inc. (the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Co |
|
| March 26, 2025 |
As filed with the Securities and Exchange Commission on March 26, 2025 As filed with the Securities and Exchange Commission on March 26, 2025 Registration No. |
|
| March 26, 2025 |
As filed with the Securities and Exchange Commission on March 26, 2025 As filed with the Securities and Exchange Commission on March 26, 2025 Registration No. |
|
| March 26, 2025 |
Form of Perspective Therapeutics, Inc. Stock Option Agreement. Exhibit 10.4 PERSPECTIVE THERAPEUTICS, INC. STOCK OPTION AGREEMENT Perspective Therapeutics, Inc. has granted to the individual (the “Participant”) named in the Notice of Grant of Stock Option (the “Notice”) to which this Stock Option Agreement (the “Option Agreement”) is attached an option (the “Option”) to purchase certain shares of Common Stock upon the terms and conditions set forth in the Not |
|
| March 26, 2025 |
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results • On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of one potential new medicine, all based on our next generation targeted radiopharmaceutical technology platform • Enrollment ongoing |
|
| March 26, 2025 |
As filed with the Securities and Exchange Commission on March 26, 2025 As filed with the Securities and Exchange Commission on March 26, 2025 Registration No. |
|
| March 26, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Perspective Therapeutics, Inc. |
|
| March 26, 2025 |
Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti |
|
| March 17, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 17, 2025 |
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma SEATTLE – March 17, 2025 – Perspective, Therapeutics, Inc. |
|
| March 4, 2025 |
Corporate Presentation Developing the Next Generation of Targeted Therapies Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window Proposed Mechani |
|
| March 4, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 14, 2025 |
Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. |
|
| February 3, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 03, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C |
|
| February 3, 2025 |
Corporate Presentation February 2025 NYSE AMERICAN: CATX Corporate Presentation February 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 24, 2025 |
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium • Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2. |
|
| January 24, 2025 |
Investor Call ASCO-GI 2025 Presentation January 24, 2025 NYSE AMERICAN: CATX Investor Call ASCO-GI 2025 Presentation January 24, 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 13, 2025 |
Corporate Presentation January 2025 NYSE AMERICAN: CATX Corporate Presentation January 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. |
|
| January 13, 2025 |
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J. |
|
| January 6, 2025 |
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer Exhibit 99.1. Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer SEATTLE, WASHINGTON – January 6, 2025 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company’s Chi |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 02, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co |
|
| December 4, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 03, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C |
|
| December 4, 2024 |
Corporate Presentation December 2024 NYSE AMERICAN: CATX Corporate Presentation December 2024 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. |
|
| November 21, 2024 |
Investor Call NANETS 2024 Presentation November 21, 2024 NYSE AMERICAN: CATX Investor Call NANETS 2024 Presentation November 21, 2024 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C |
|
| November 21, 2024 |
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium • [212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2. |
|
| November 15, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C |
|
| November 15, 2024 |
Corporate Presentation November 2024 NYSE AMERICAN: CATX Corporate Presentation November 2024 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. |
|
| November 14, 2024 |
CATX / Perspective Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Perspective Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 46489V302 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 14, 2024 |
CATX / Perspective Therapeutics, Inc. / Avidity Partners Management LP Passive Investment SC 13G 1 d1153051713-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Perspective Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 46489V302 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 12, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]” HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Phone: (206) 676-0900 2401 Elliott Ave., Suite 320 Toll Free: (877) 447-6729 Seattle, WA 98121 https://perspectivetherapeutics.com August 19, 2024 Mark Austin [***] Re: Terms of S |
|
| November 12, 2024 |
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results • Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21st International Congress of the Society of Melanoma Research in Oct |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-3340 |
|
| October 11, 2024 |
Exhibit 99.1 Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research • [212Pb]VMT01 was observed to be safe, and no dose-limiting toxicities were observed at the two doses tested (3.0 and 5.0 mCi) • Prolonged progression-free survival and tu |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) ( |
|
| September 20, 2024 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. STATEMENT OF WORK NO. 1 PURSUANT TO MASTER EQUIPMENT AND SERVICES AGREEMENT This Statement of Work No. 1 (“SOW No. 1”) dated effective September 18, 2024, entered into by Perspec |
|
| September 20, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MASTER EQUIPMENT AND SERVICES AGREEMENT THIS MASTER EQUIPMENT AND SERVICES AGREEMENT (“Agreement”) is dated effective as of September 18, 2024 (“Effective Date”) by and between P |
|
| September 5, 2024 |
Exhibit 99.1 Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma SEATTLE – September 5, 2024 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that the U.S. Fo |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 05, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) ( |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 14, 2024 |
As filed with the Securities and Exchange Commission on August 13, 2024 As filed with the Securities and Exchange Commission on August 13, 2024 Registration No. |
|
| August 14, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Perspective Therapeutics, Inc. |
|
| August 13, 2024 |
Exhibit 1.1 Perspective Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement August 13, 2024 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 RBC Capital Markets, LLC 200 Vesey Street New York, NY 10281 Ladies and Gentlemen: Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “ |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33407 PER |
|
| August 13, 2024 |
Exhibit 10.2 ISORAY, INC. 2017 EQUITY INCENTIVE PLAN (Conformed Version Reflecting Reverse Stock Split Effective June 14, 2024) 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the IsoRay, Inc. 2017 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable IsoRay, Inc., a Minnesota corporation (the “Company”), and any Affiliate to attract and retain the t |
|
| August 13, 2024 |
Up to $250,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279692 PROSPECTUS SUPPLEMENT (To Prospectus dated May 24, 2024) Up to $250,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”), dated as of August 13, 2024, with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (each, an “Agent” and, collectively, the “Agents”), relating to the sa |
|
| August 13, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 13, 2024 |
Corporate Presentation August 2024 NYSE: CATX Corporate Presentation August 2024 NYSE: CATX Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. |
|
| August 13, 2024 |
Exhibit 10.1 PERSPECTIVE THERAPEUTICS, INC. THIRD AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN (AMENDED AND RESTATED MAY 31, 2024) (Conformed Version Reflecting Reverse Stock Split Effective June 14, 2024) 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan (the “Plan”). The purposes of t |
|
| August 13, 2024 |
Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Perspective Therapeutics, Inc. |
|
| August 12, 2024 |
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results • Completed enrollment of initial Cohort 2 patients in its VMT-α-NET and VMT01 clinical trials • On track to advance multiple pre-IND assets into the clinic in the next 12-18 months • Making continued progress on build out of manufacturing infrastructure • Cash, cash equivalents and short-term investments balance of approximately $293 million expected to be sufficient to fund our current planned operations and capital investments into mid-2026 SEATTLE – August 12, 2024 – Perspective Therapeutics, Inc. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C |
|
| August 12, 2024 |
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results • Continued progress enrolling in its VMT-α-NET and VMT01 clinical trials • Disclosed a new internally discovered molecule that targets fibroblast activation protein-α • Announced the in-licensing of a technology that enables the use of antibodies to direct radiolabeled ligands to tumor sit |
|
| June 14, 2024 |
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split Exhibit 99.1 Perspective Therapeutics Announces 1-for-10 Reverse Stock Split SEATTLE, WASHINGTON – June 11, 2024 – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will effect a 1-for-10 reverse stock split, effective at 4:0 |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 14, 2024 |
Exhibit 3.1 ANNEX A Certificate of Amendment TO THE Amended and Restated Certificate of Incorporation of PERSPECTIVE THERAPEUTICS, Inc. Perspective Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Perspective Therapeutics, In |
|
| May 31, 2024 |
Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan. Exhibit 10.1 ANNEX B perspective therapeutics, INC. THIRD AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN (EFFECTIVE May 31, 2024) 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable Perspective Therapeutics, Inc., a Delaware corporati |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 29, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: [•], 2024 Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder”), is |
|
| May 29, 2024 |
Exhibit 1.1 Perspective Therapeutics, Inc. 51,515,880 Shares of Common Stock Pre-Funded Warrants to Purchase 1,464,252 Shares of Common Stock UNDERWRITING AGREEMENT Dated: May 24, 2024 Perspective Therapeutics, Inc. 51,515,880 Shares of Common Stock Pre-Funded Warrants to Purchase 1,464,252 Shares of Common Stock UNDERWRITING AGREEMENT May 24, 2024 BofA Securities, Inc. as Representative of the se |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 29, 2024 |
Exhibit 99.1 Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants SEATTLE, May 24, 2024 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwri |
|
| May 24, 2024 |
Exhibit 4.6 INDENTURE DATED AS OF , 20 BETWEEN PERSPECTIVE THERAPETUICS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series i TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions. 1 Section 1.02 Compliance Certificates and Opinions. 6 Section 1.03 Form of Documents Delivered to Trustee. 6 Section 1.04 A |
|
| May 24, 2024 |
As filed with the Securities and Exchange Commission on May 24, 2024 As filed with the Securities and Exchange Commission on May 24, 2024 Registration No. |
|
| May 24, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Perspective Therapeutics, Inc. |
|
| May 24, 2024 |
51,515,880 Shares of Common Stock Pre-Funded Warrants to Purchase 1,464,252 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279692 Prospectus Supplement (To prospectus dated May 24, 2024) 51,515,880 Shares of Common Stock Pre-Funded Warrants to Purchase 1,464,252 Shares of Common Stock We are offering 51,515,880 shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,464,252 shares of our common stock pursuant |
|
| May 24, 2024 |
Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated May 24, 2024 Relating to Prospectus Dated May 24, 2024 Registration Statement No. |
|
| May 24, 2024 |
Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Perspective Therapeutics, Inc. |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 20, 2024 |
Exhibit 99.1 Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 SEATTLE, WASHINGTON – May 20, 2024 – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Perspective Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33407 (Commission File Number) 41-1458152 (IRS Employer Identification No.) 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 (Address of |
|
| May 15, 2024 |
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results • Continued progress enrolling in its VMT-α-NET and VMT01 clinical trials • Disclosed a new internally discovered molecule that targets fibroblast activation protein-α • Announced the in-licensing of a technology that enables the use of antibodies to direct radiolabeled ligands to tumor sit |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. |
|
| April 19, 2024 |
CATX / Perspective Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 16, 2024 |
Unaudited Pro Forma Condensed Consolidated Financial Information Unaudited Pro Forma Condensed Consolidated Financial Information Brachytherapy Asset Disposition On December 7, 2023, Isoray Medical, Inc. |
|
| April 16, 2024 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 9, 2024 |
148,352,336 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-278362 PROSPECTUS 148,352,336 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus under the caption “Selling Stockholders,” of up to 148,352,336 shares of our common stock, par value $0.001 per share. We are not selling any shares of common sto |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 8, 2024 |
Exhibit 16.1 April 8, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated April 8, 2024, of Perspective Therapeutics, Inc. and are in agreement with the statements contained in the second, fourth, fifth, and sixth sentences therein. We have no basis to agree or disagree with other statements of the registrant conta |
|
| April 8, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 05, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 8, 2024 |
PERSPECTIVE THERAPEUTICS, INC. 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 PERSPECTIVE THERAPEUTICS, INC. 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 April 8, 2024 VIA EDGAR Office of Industrial Applications and Services Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Conlon Danberg Re: Perspective Therapeutics, Inc. Registration Statement on Form S-3 Filed March 29, 2024 File No. 333-27 |
|
| April 3, 2024 |
Exhibit 2.1 CONFIDENTIAL AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT This AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this "Amendment”), dated as of March 28, 2024, is by and among Isoray Medical, Inc., a Delaware corporation (“Seller”), Perspective Therapeutics, Inc., a Delaware corporation (“Seller Parent”), and GT Medical Technologies, Inc., a Delaware corporation (“Buyer,” and together with S |
|
| April 3, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33407 (Commission File |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
Exhibit107 Calculation of Filing Fee Table Form S-8 (Form Type) Perspective Therapeutics, Inc. |
|
| March 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Perspective Therapeutics, Inc. |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 29, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 29, 2024 Registration No. |
|
| March 28, 2024 |
Exhibit 21.1 Subsidiaries of the Company Isoray Medical, Inc., a Delaware corporation Isoray International, LLC, a Washington limited liability company Viewpoint Molecular Targeting, Inc. a Delaware corporation Perspective Therapeutics Pty Ltd, an Australian Company |
|
| March 28, 2024 |
Exhibit 97 PERSPECTIVE THERAPEUTICS, INC. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Perspective Therapeutics, Inc. (the “Company”) on November 15, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the |
|
| March 28, 2024 |
Exhibit 10.26 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 22, 2024, between Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), and Lantheus Alpha Therapy, LLC, a Delaware limited liability company (the “Investor”). RECITALS This Agreement is made pursuant to the Investment Agreement, dated as of Jan |
|
| March 28, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-33407 Perspective |
|
| March 28, 2024 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Perspective Therapeutics, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), |
|
| March 28, 2024 |
Exhibit 10.6 FORM OF INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20, but effective as of [●], between Perspective Therapeutics, Inc., a Delaware corporation (“Perspective” or the “Company”), and (“Indemnitee”). WHEREAS: 1. Highly competent persons have become more reluctant to serve corporations as directors and officers or in other c |
|
| March 28, 2024 |
Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results SEATTLE – March 28, 2024 – Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results f |
|
| March 28, 2024 |
Exhibit 10.28 Certain information has been excluded from this exhibit (indicated by “[***]”) because such information is both (i) not material and (ii) the type that the company treats as private or confidential. MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH PATENT LICENSE AGREEMENT This patent license agreement (“Agreement”) is by and between Mayo Foundation for Medical Education and Researc |
|
| March 28, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33407 (Commission File |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 19, 2024 |
Exhibit 99.1 Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) - Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers througho |
|
| March 19, 2024 |
Exhibit 99.2 |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 18, 2024 Perspective Therapeutics, Inc. |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 7, 2024 Perspective Therapeutics, Inc. |
|
| March 8, 2024 |
CATX / Perspective Therapeutics, Inc. / Lantheus Holdings, Inc. - SC 13D/A Activist Investment SC 13D/A 1 d749365dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 Perspective Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 46489V104 (CUSIP Number) Lantheus Holdings, Inc. 201 Burlington Road, South Building Bedford, MA 01730 Att |
|
| March 8, 2024 |
Exhibit 99.1 |
|
| March 6, 2024 |
Perspective Therapeutics Announces $87.4 Million Private Placement Exhibit 99.1 Perspective Therapeutics Announces $87.4 Million Private Placement SEATTLE, WASHINGTON – March 4, 2024 – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has entered into an investment agreement with a select gr |
|
| March 6, 2024 |
Exhibit 10.1 INVESTMENT AGREEMENT This Investment Agreement (this “Agreement”), dated as of March 4, 2024, by and among Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), with its principal place of business at 2401 Elliott Avenue, Suite 320, Seattle, Washington 98121 and each purchaser identified on Schedule 1 hereto (each, an “Investor” and collectively, the “Investors”). Ca |
|
| March 6, 2024 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT March 4, 2024 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), hereby agrees to issue and sell directly to various investors (each, an “Investor” and, collectively, the “Inve |
|
| March 6, 2024 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 6, 2024, among Perspective Therapeutics, Inc., a Delaware corporation (the “Company”) and each of the several purchasers identified on Schedule 1 to the Investment Agreement (defined below) (each, an “Investor” and collectively, the “Investors”). RECITALS This Agree |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 6, 2024 |
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility Exhibit 99.2 Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility SEATTLE, WASHINGTON – March 05, 2024 – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art m |
|
| February 5, 2024 |
Exhibit 99.1 |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 5, 2024 Perspective Therapeutics, Inc. |
|
| February 1, 2024 |
CATX / Perspective Therapeutics, Inc. / Lantheus Holdings, Inc. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Perspective Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 46489V104 (CUSIP Number) Lantheus Holdings, Inc. 201 Burlington Road, South Building Bedford, MA 01730 Attention: Daniel Niedzwiecki (978) 671-8001 (Name, A |
|
| February 1, 2024 |
EX-99.4 2 d785059dex994.htm EX-99.4 Exhibit 99.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 22, 2024, between Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), and Lantheus Alpha Therapy, LLC, a Delaware limited liability company (the “Investor”). RECITALS This Agreement is made pursuant to the In |
|
| February 1, 2024 |
EX-99.7 5 d785059dex997.htm EX-99.7 EXHIBIT 99.7 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Perspective Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Date: February 1, 2024 LANTHEUS HOLDINGS, INC. By: /s/ |
|
| February 1, 2024 |
Power of Attorney (Lantheus Holdings, Inc.) EX-99.5 3 d785059dex995.htm EX-99.5 Exhibit 99.5 POWER OF ATTORNEY Know all by these presents, that Lantheus Holdings, Inc. (the “Company”) hereby constitutes and appoints each of Dan Niedzwiecki, Eric Green and Dustin Hawks of the Company and Jill Simon of Cooley LLP, signing singly, and with full power of substitution, the Company’s true and lawful attorneys-in-fact and agents to: (1) prepare, e |
|
| February 1, 2024 |
Power of Attorney (Lantheus Alpha Therapy, LLC) EX-99.6 4 d785059dex996.htm EX-99.6 EXHIBIT 99.6 POWER OF ATTORNEY Know all by these presents, that Lantheus Alpha Therapy, LLC (the “Company”) hereby constitutes and appoints each of Dan Niedzwiecki, Eric Green and Dustin Hawks of the Company and Jill Simon of Cooley LLP, signing singly, and with full power of substitution, the Company’s true and lawful attorneys-in-fact and agents to: (1) prepar |
|
| January 22, 2024 |
Exhibit 99.3 Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement SEATTLE, January 22, 2024 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the closing of its previously |
|
| January 22, 2024 |
Exhibit 1.1 132,075,218 Shares of Common Stock Pre-Funded Warrants to Purchase 30,086,944 Shares of Common Stock Perspective Therapeutics, Inc. UNDERWRITING AGREEMENT January 17, 2024 Oppenheimer & Co. Inc. as Representative of the several Underwriters named in Schedule I hereto 85 Broad Street New York, NY 10004 Ladies and Gentlemen: Perspective Therapeutics, Inc., a Delaware corporation (the “Co |
|
| January 22, 2024 |
Exhibit 99.2 Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement SEATTLE, January 18, 2024 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten |
|
| January 22, 2024 |
Perspective Therapeutics Announces Proposed Public Offering Exhibit 99.1 Perspective Therapeutics Announces Proposed Public Offering SEATTLE, January 17, 2024 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has commenced an underwritten public offering of shares of its common stoc |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 22, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: [•], 2024 Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder”), is |
|
| January 18, 2024 |
132,075,218 Shares of Common Stock Pre-Funded Warrants to Purchase 30,086,944 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275638 Prospectus Supplement (To prospectus dated December 14, 2023) 132,075,218 Shares of Common Stock Pre-Funded Warrants to Purchase 30,086,944 Shares of Common Stock We are offering 132,075,218 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 30,086,944 shares of ou |
|
| January 17, 2024 |
Exhibit 10.2 Certain information has been excluded from this exhibit (indicated by “[***]”) because such information is both (i) not material and (ii) the type that the company treats as private or confidential. ASSET PURCHASE AGREEMENT by and between PROGENICS PHARMACEUTICALS, INC., as Seller, PERSPECTIVE THERAPEUTICS, INC., as Purchaser, AND For purposes of Section 9.12 only LANTHEUS MEDICAL IMA |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of I |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 17, 2024 Perspective Therapeutics, Inc. |
|
| January 17, 2024 |
Exhibit 99.1 Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01 SEATTLE – January 17, 2024 – Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in clinical studies for both of its lead product candidates, [21 |
|
| January 17, 2024 |
Exhibit 10.3 Certain information has been excluded from this exhibit (indicated by “[***]”) because such information is both (i) not material and (ii) the type that the company treats as private or confidential. OPTION AGREEMENT This Option Agreement (this “Agreement”) is dated as of January 8, 2024 (the “Effective Date”) by and between Lantheus Alpha Therapy, LLC, a Delaware limited liability com |
|
| January 17, 2024 |
Exhibit 10.1 Certain information has been excluded from this exhibit (indicated by “[***]”) because such information is both (i) not material and (ii) the type that the company treats as private or confidential. INVESTMENT AGREEMENT This Investment Agreement (this “Agreement”), dated as of January 8, 2024, by and between Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), with |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 17, 2024 |
Exhibit 99.1 |
|
| January 17, 2024 |
SUBJECT TO COMPLETION, DATED JANUARY 17, 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-275638 The information in this preliminary prospectus supplement is not complete and may be changed. The registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and |
|
| January 11, 2024 |
Exhibit 99.1 Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability - Lantheus will have the option to negotiate an exclusive license to Perspective Therapeutics’ Pb212-VMT-α-NET - Lantheus will have the option to co-fund and negotiate an exclusive license for certain early-stage therape |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 31, 2023 Perspective Therapeutics, Inc. |
|
| January 5, 2024 |
Exhibit 99.1 Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment - Mayo Clinic’s PSMA Alpha-PET DoubLET platform allows for imaging and targeted therapy with alpha and/or beta-particle radiopharmaceutical therapy (RPT) using a novel 64/67Cu and 203/212Pb double chelator design. - PSMA Alpha-PET DoubLET l |
|
| January 3, 2024 |
Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference Exhibit 99.1 Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference SEATTLE – January 2, 2024 – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company’s Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 1 |
|
| January 3, 2024 |
EX-99.2 3 ex611241.htm EXHIBIT 99.2 Exhibit 99.2 |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 2, 2024 Perspective Therapeutics, Inc. |
|
| December 13, 2023 |
PERSPECTIVE THERAPEUTICS, INC. 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 PERSPECTIVE THERAPEUTICS, INC. 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 December 13, 2023 VIA EDGAR Office of Industrial Applications and Services Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Benjamin Richie Margaret Schwartz Re: Perspective Therapeutics, Inc. Registration Statement on Form S-3, as amended F |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 7, 2023 Perspective Therapeutics, Inc. |
|
| December 12, 2023 |
Perspective Therapeutics Divests Brachytherapy Business Exhibit 99.1 Perspective Therapeutics Divests Brachytherapy Business SEATTLE – December 12, 2023 – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced it agreed to fully divest its brachytherapy business, including its radioactive Cesium-131 seed assets and related business infrastructure, to GT Medical Technologies, Inc. (“GT Medical”). The trans |
|
| December 12, 2023 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT by and between Isoray Medical, Inc. as Seller, Perspective Therapeutics, Inc. as Seller Parent and GT Medical Technologies, Inc. as Buyer dated as of December 7, 2023 TABLE OF CONTENTS Page 1. Definitions 1 1.1 Defined Terms 1 1.2 Additional Defined Terms 15 1.3 Other Definitional and Interpretive Matters 16 2. Purchase and Sale of the Business 17 2.1 Purchase |
|
| December 8, 2023 |
Exhibit 99.1 Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors - First U.S. patient with refractory or relapsed SSTR2-positive neuroendocrine tumors treated with [212Pb]VMT-α-NET - Preliminary data readout expected in second half of 2024 SEATTLE – December 7, 2023 – Perspective Therapeutics, Inc. (“ |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 7, 2023 Perspective Therapeutics, Inc. |
|
| December 7, 2023 |
As filed with the Securities and Exchange Commission on December 6, 2023 Table of Contents As filed with the Securities and Exchange Commission on December 6, 2023 Registration No. |
|
| December 6, 2023 |
December 6, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N. |
|
| December 6, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[**]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Contract № 840/08625142/31/192-23 Date: 12/5/2023 THE SELLER Isotope-Regional Alliance, Joint Stock Company (JSC «Isotope») Pogodinskaya str., 22, Moscow, 119435, Russia. Phone: + |
|
| December 6, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co |
|
| November 28, 2023 |
Exhibit 99.2 Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany - Imaging was conducted as part of a clinical study at Technical University of Dresden in Germany - Image was selected as “Image of the Month” in the European Journal of Nuclear Medicine and Molecular Imaging, November 2023 - Radiolabeling was performed on-si |
|
| November 28, 2023 |
Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals Exhibit 99.1 Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals SEATTLE – November 27, 2023 – Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s discovery pipeline. The studies were published in the European Journal of Nuclear Medicine and Molecular Imaging, |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 27, 2023 Perspective Therapeutics, Inc. |
|
| November 28, 2023 |
Exhibit 99.3 |
|
| November 17, 2023 |
As filed with the Securities and Exchange Commission on November 17, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 17, 2023 Registration No. |
|
| November 17, 2023 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Perspective Therapeutics, Inc. |
|
| November 17, 2023 |
Form of Indenture (filed herewith). Exhibit 4.3 INDENTURE DATED AS OF , 20 BETWEEN PERSPECTIVE THERAPETUICS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series i TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions. 1 Section 1.02 Compliance Certificates and Opinions. 6 Section 1.03 Form of Documents Delivered to Trustee. 6 Section 1.04 A |
|
| November 17, 2023 |
Exhibit 1.2 Perspective Therapeutics, Inc. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement November 17, 2023 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 JonesTrading Institutional Services LLC 325 Hudson Street, 6th Floor New York, New York 10013 Ladies and Gentlemen: Perspecti |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C |
|
| November 15, 2023 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-227909 PROSPECTUS SUPPLEMENT NO. 20 (To Prospectus filed with Form S-1 on October 19, 2018, as amended by Amendment No. 1 to Form S-1 filed on December 10, 2018, and as supplemented by Prospectus Supplement No. 1 filed on February 14, 2019, Prospectus Supplement No. 2 filed on May 13, 2019, Prospectus Supplement No. 3 filed on |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. |
|
| November 14, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 14, 2023 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33407 (Commission F |
|
| November 14, 2023 |
Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Agreement and General Release (the “Agreement”) is being entered into between Jennifer Streeter (“Employee”) and Perspective Therapeutics, Inc. (the “Company”) in connection with the without cause termination of Employee’s employment with the Company as of July 14, 2023 (the “Separation Date”). 1. Final |
|
| November 14, 2023 |
Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights Exhibit 99.1 Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights SEATTLE – November 14, 2023 – Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced third quarter financial results for the period ended September 30, 2023 and provided recent business highlights. “Our commitment to advancing targeted alpha-particle therapies against neuro |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 6, 2023 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33407 (Commission Fil |
|
| October 12, 2023 |
Exhibit 10.1 PERSPECTIVE THERAPEUTICS, INC. SECOND AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN (EFFECTIVE OCTOBER 6, 2023) 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Perspective Therapeutics, Inc. Second Amended and Restated 2020 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable Perspective Therapeutics, Inc., a Delaware corporation |
|
| September 5, 2023 |
Exhibit 99.1 |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 1, 2023 Perspective Therapeutics, Inc. |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 18, 2023 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-227909 PROSPECTUS SUPPLEMENT NO. 19 (To Prospectus filed with Form S-1 on October 19, 2018, as amended by Amendment No. 1 to Form S-1 filed on December 10, 2018, and as supplemented by Prospectus Supplement No. 1 filed on February 14, 2019, Prospectus Supplement No. 2 filed on May 13, 2019, Prospectus Supplement No. 3 filed on |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 11, 2023 Perspective Therapeutics, Inc. |
|
| August 11, 2023 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Quarterly Report on Form 10-Q of which this exhibit forms a part, the only class of securities of Perspective Therapeutics, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act” |
|
| August 11, 2023 |
Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights Exhibit 99.1 Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights ● Phase I/2a clinical trials initiated: VMT- α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023. ● First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma. R |
|
| August 8, 2023 |
As filed with the Securities and Exchange Commission on August 8, 2023 As filed with the Securities and Exchange Commission on August 8, 2023 Registration No. |
|
| August 8, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) PERSPECTIVE THERAPEUTICS, INC. |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2023 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2023 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 13, 2023 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-227909 PROSPECTUS SUPPLEMENT NO. 17 (To Prospectus filed with Form S-1 on October 19, 2018, as amended by Amendment No. 1 to Form S-1 filed on December 10, 2018, and as supplemented by Prospectus Supplement No. 1 filed on February 14, 2019, Prospectus Supplement No. 2 filed on May 15, 2019, Prospectus Supplement No. 3 filed on |
|
| July 13, 2023 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-227909 PROSPECTUS SUPPLEMENT NO. 18 (To Prospectus filed with Form S-1 on October 19, 2018, as amended by Amendment No. 1 to Form S-1 filed on December 10, 2018, and as supplemented by Prospectus Supplement No. 1 filed on February 14, 2019, Prospectus Supplement No. 2 filed on May 15, 2019, Prospectus Supplement No. 3 filed on |
|
| June 23, 2023 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made by and between Jonathan Hunt (“Executive”) and Perspective Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is effective as of June 1, 2023 (the “Effective Date”). WHEREAS, the Company is engaged in the business of providing innovative solutions for the treatment of malignancies using medica |
|
| June 23, 2023 |
Executive Employment Agreement, dated June 16, 2023, by and between the Company and Johan Spoor Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made by and between Johan Spoor (“Executive”) and Perspective Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is effective as June 1, 2023 (the “Effective Date”). WHEREAS, the Company is engaged in the business of providing innovative solutions for the treatment of malignancies using medical iso |
|
| June 23, 2023 |
Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made by and between Markus Puhlmann, M.D. (“Executive”) and Perspective Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is effective as of June 1, 2023 (the “Effective Date”). WHEREAS, the Company is engaged in the business of providing innovative solutions for the treatment of malignancies usin |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 16, 2023 Perspective Therapeutics, Inc. |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Perspective Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33407 (Commission File Number) 41-1458152 (IRS Employer Identification No.) 350 Hills Street, Suite 106, Richland, WA 99354 (Address of principa |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 9, 2023 Perspective Therapeutics, Inc. |
|
| May 15, 2023 |
Exhibit 10.11 LEASE DOCUMENT FOR THE UNIVERSITY OF IOWA BIOVENTURES CENTERch THE LEASE MADE AND ENTERED INTO THIS 21st day of February , 2023, by and between Board of Regents, State of Iowa, for the use and benefit of the University of Iowa, hereinafter referred to as LESSOR, and Viewpoint Molecular Targeting, hereinafter referred to as the LESSEE. LESSOR and LESSEE are jointly referred to as the |
|
| May 15, 2023 |
Exhibit 10.13 PROMISSORY NOTE Principal Loan Date Maturity Loan No Call/ Coll Account Officer $1,771,250.00 12-29-2022 12-29-2027 8079917501 1E / 502 VAA2811 JLSTUL References in the boxes 1:1bove are for Lender's use only and do not limit the applicability of this document to any particular loan or item. An item above containing "***" has been omitted due to text length limitations. Borrower: Vie |
|
| May 15, 2023 |
Exhibit 10.9 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH KNOW-HOW LICENSE AGREEMENT This know-how license agreement (“Agreement”), made as of this 24th day of January 2022 (the “Effective Date”), is by and between Mayo Foundati |
|
| May 15, 2023 |
Exhibit 10.8 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN THE UNIVERSITY OF IOWA RESEARCH FOUNDATION AND VIEWPOINT MOLECULAR TARGETING This Fourth Amendment (“Fourth Amendment”) is effective as of June 12, 2020 (“Eff |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. |
|
| May 15, 2023 |
Exhibit 10.5 FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN THE UNIVERSITY OF IOWA RESEARCH FOUNDATION AND VIEWPOINT MOLECULAR TARGETING This First Amendment ("First Amendment") is effective as of August 1, 2018 ("Effective Date"), and serves as a modification to the License Agreement ("Agreement") having an effective date of June 5, 2018, made by and between the University of Iowa |
|
| May 15, 2023 |
Exhibit 10.4 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN THE UNIVERSITY OF IOWA RESEARCH FOUNDATION AND VIEWPOINT MOLECULAR TARGETING This license agreement (“Agreement”) effective as of June 5, 2018 (“Effective Date”) is by and betwee |
